The Atlas, Priced: Every Condition One Molecule Moved

Two molecules booked $71 billion in 2025. Semaglutide and tirzepatide, the GLP-1 drugs, brought in more than double the combined revenue of OpenAI and Anthropic. Tirzepatide is now the best-selling drug on earth.

They were never sixty-one conditions

In January 2025, Washington University followed 215,970 patients on these drugs, matched against controls, across 175 conditions. Risk fell on 42. It rose on 19.

Sixty-one conditions moved on one molecule. Even the nineteen that moved the wrong way make the same point as the forty-two that improved: this is one system wearing sixty-one names.

A hormone is a chemical messenger that travels in the blood, so it reaches every tissue the blood reaches. Nothing about the molecule changes between tissues. Only the cell receiving it. GLP-1 receptors sit on the pancreas, in the hypothalamus, on the stomach lining, and in the brain's reward circuitry. The drug does not report to a department. It goes everywhere at once.

Healthcare is not designed that way. It is built by organ, by sub-system. Endocrinology, cardiology, nephrology, pulmonology, hepatology, addiction. Separate boards, separate journals, separate clinics, separate billing codes. That structure came from how you train a doctor, how you pay one, and how you bill a symptom. It never came from human health.

Now read the approval sequence with that in mind. Diabetes. Then obesity in 2021. Then a 20% cut in major cardiovascular events. Then 24% on kidney outcomes. Then sleep apnea. Then liver disease. Addiction is in the data and waiting on confirmatory trials.

That is not a drug pipeline. It is an inventory of the American sick-care economy, and each new approval crosses off another line item.

Insulin and continuous glucose monitoring. Bariatric surgery. Cardiac devices and stents. Dialysis. CPAP and hypoglossal nerve stimulators. Transplant. Rehab. Every one of those is a public company or a division of one, and every one of them has revenue that is a direct function of how many Americans stay sick.

Xie, Choi & Al-Aly · Nature Medicine · 2,013,415 patient records · 175 outcomes

The atlas, priced.

Every confirmed condition the molecule moved, and what the United States spends each year on the disease areas it touches. Click any condition for the effect size, the cost anchor, and the incumbent it reprices.

conditions with reduced risk vs usual care

conditions with increased risk vs usual care

$1.0T

published direct-medical cost anchors on the reduced-risk side, per year

$3.9T

adding published societal estimates: lost productivity, caregiving, value-of-life

Read the totals as exposure, not arithmetic. Categories overlap (a diabetic heart-failure patient is counted in both), vintages span 2000–2026, and the societal figures lean on value-of-life accounting. Every anchor is labeled with its scope and year, and the toggle separates them.

Select a condition.

Start with cardiac arrest, hepatic failure, or opioid use disorders. The pattern is the same everywhere: a modest per-patient effect, multiplied by an enormous prevalence, applied against an industry built on the disease staying.

Effect sizes are hazard ratios for GLP-1RA initiation vs continued usual care in US Veterans Affairs data: 215,970 initiators against 1,203,097 controls, median follow-up 3.68 years, cohort 94.7% male, median age about 64, all with diabetes. Associations, not randomized trials, and most effects are 10–25%. 37 of the 42 reduced-risk and 17 of the 19 increased-risk outcomes are named in the paper's text and shown here; the remainder sit in its supplementary tables. Cost anchors keep their published scope and year, unadjusted.

Source: Xie Y, Choi T, Al-Aly Z, “Mapping the effectiveness and risks of GLP-1 receptor agonists,” Nature Medicine 31:951–962 (2025), DOI 10.1038/s41591-024-03412-w, via PubMed; author correction 10.1038/s41591-025-03542-9. Cost anchors: CDC, CMS, AHA 2026 Statistical Update, ADA, USRDS/NIDDK, Alzheimer's Association 2026, AHRQ HCUP 2022, CDC MMWR 2021, and peer-reviewed burden studies; every figure is linked in Sources.

One by one, GLP-1 breaks entrenched markets

It took one afternoon.

On the day Novo said the kidney trial had been stopped early for benefit, DaVita and Fresenius each fell about 17%. Dialysis runs about 1% of the entire federal budget, two firms hold most of it, and three quarters of kidney failure traces back to diabetes and high blood pressure. A drug that slows kidney decline shrinks the population those companies exist to serve.

Nobody had to win that argument. The stock settled it before lunch.

Then the market went back to modeling next quarter's treatment volumes.

The repricing of healthcare is being ignored. No one can wrap their mind around the idea that chronic disease might actually go away. A 2040 thesis does not pay a 2026 bonus. It is why our favorite unicorns feel they can wait to innovate around human health: the fire drills of chronic disease will always keep running hot.